Endotec Calls FDA’s AIP Decision “Extreme,” Probes Appeal Mechanisms
This article was originally published in The Gray Sheet
Executive Summary
Endotec is asking CDRH Ombudsman Les Weinstein to assist in obtaining a formal review of the FDA's Feb. 14 decision to invoke an application integrity policy (AIP) for the firm's submissions